AstraZeneca plc (ADR) (AZN), Novartis AG (ADR) (NVS): 5 Biotech Giants with Lucrative Dividend Yields

Page 1 of 2

Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance. Biotech companies go through a series of clinical trials toward FDA approval and market launch. Any update of the trial can potentially cause the shares to shoot up or go down. Competitors’ activities and drug issues can affect the shares, as well.

The triumphs and falls of the competitors are sometimes used by traders as a benchmark for trends and outlook. Adverse events impacting one drug will shake the shares of many pharmaceutical companies. It will not only pull down the shares of the company carrying the drug but also those of its peers. This further contributes to the volatility of biotech stocks.

Despite the high risk of investing in biotechs, you can minimize the risk by adding filters. One of them is choosing only large cap companies that are more stable. Aside from that, going for high-yielding dividend stocks can further improve your earnings or minimize your loss. Therefore, a good investing strategy would be to choose large cap biotech stocks with high yields. Here are some stocks that fit the bill.

AstraZeneca plc (ADR) (NYSE:AZN)

AstraZeneca plc (ADR) (NYSE:AZN)

Currently yields 7.27% and plans to buy Omthera Pharmaceutical.

AstraZeneca plc (ADR) (NYSE:AZN) is one of the highest yielding biotech stocks. Its forward annualized dividend is $3.80 per share based on the latest semi-annual dividend of $1.9 per share. The annualized dividend has also been increasing year-over-year for the last five years.

AstraZeneca plc (ADR) (NYSE:AZN) plans to acquire Omthera Pharmaceutical for an estimated $443 million. This will be done via an Omthera stock purchase at a premium price of 88% of its May 24, 2013 closing price.

Omthera has several drug candidates in Phase III trials. In 2012, the company reported positive results for ESPIRIT and EVOLVE. These drugs are expected to get approval within the year. If the acquisition plan pushes through, this will further strengthen the portfolio of AstraZeneca plc (ADR) (NYSE:AZN).

Novartis AG (ADR) (NYSE:NVS)

Another good dividend stock, Novartis AG (ADR) (NYSE:NVS)’s annualized dividend is $2.53 per share, or 3.48%. Unlike many stocks that pay quarterly dividends, Novartis pays dividends once per year. The dividend amount has also been increasing every year since 2001.

Novartis AG (ADR) (NYSE:NVS) is a well-diversified firm with numerous subsidiaries. One of them is a global leader in eye care, Alcon. In April, Alcon announced FDA approval of Simbrinza Suspension, a medicine for the treatment of elevated intraocular pressure (IOP).

Novartis AG (ADR) (NYSE:NVS) further reported positive results for its breakthrough therapy for patients with ALK+ non-small cell lung cancer called LDK378. These developments will arguably boost investor confidence in the company.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Also a mega-cap biotech stock with attractive dividend yield, GlaxoSmithKline pays a forward annualized dividend is $2.2 per share, or 4.23%. Yearly dividend growth has beeen seen since 2009.

GlaxoSmithKline announced on June 1, 2013 that the Phase III clinical results for VOTRIENT (pazopanib) met the primary objective. This drug candidate was designed as a maintenance therapy in women with advanced epithelial ovarian cancer.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!